Quick Answer
Non-comedogenic is a test result, not an ingredient list. Back it with a human comedogenicity test or an in-use test on acne-prone volunteers, run on your final formula and usually booked through your Korean ODM. Korea already expects proof, such as human test data, for its “suitable for acne-prone skin” claim. The US has no definition at all, so FTC substantiation rules decide how far your data reaches.
Non-comedogenic sits on the front of moisturizers, sunscreens and foundations all over US shelves. It reads like a simple label word. It is not. Nobody approves it in advance, in Korea or in the US, and the brand on the label is the one holding the proof.
If the word is on your wish list, plan the test now, before the formula is final. This guide covers which test supports which wording and what Korean rules already expect from your ODM. It also lays out the steps in order and the phrases that turn a cosmetic into an acne drug.
Key Takeaways
- Non-comedogenic describes how a finished product behaves in a test. Ingredient ratings do not prove it.
- Two human designs fit: the back-patch comedogenicity model and an in-use test on acne-prone skin.
- Korea treats “suitable for acne-prone skin” as a claim that must be proven, typically with human test data.
- In the US, “helps prevent new blemishes” is OTC acne drug language. “Won’t clog pores” stays cosmetic.
- Lock the formula, write the claim, then book the test.
What Does Non-Comedogenic Mean on a US Label?
Non-comedogenic is a cosmetic claim that a product does not tend to cause comedones. No US regulation defines it. FDA keeps no list of approved cosmetic claims and requires that labeling be truthful and not misleading, as its cosmetics labeling claims page explains.
A comedone is a clogged hair follicle. Open ones look like blackheads and closed ones look like whiteheads. The claim tells shoppers your product will not build those plugs.
FDA’s claims page has explainers for words like hypoallergenic and organic. The pore claim is not on the list. Ads fall under the Federal Trade Commission, which requires a reasonable basis for any objective claim before it runs (FTC policy statement on advertising substantiation). If your ad says “tests prove” or “studies show,” the FTC expects at least the level of proof you advertise.
Ingredient Ratings Don’t Prove a Non-Comedogenic Claim
Ingredient ratings came mostly from animal tests on single raw materials, and a finished formula does not behave like its raw materials. The proof has to come from the product you will sell.
The old lists trace back to the rabbit ear model. When Mills and Kligman built a human model in 1982, they reported that the rabbit model was more sensitive than the human one (Arch Dermatol, PubMed). In 2006, Draelos and DiNardo patched finished products on the upper backs of comedone-prone volunteers. Their conclusion: finished products using comedogenic ingredients are not necessarily comedogenic (J Am Acad Dermatol, PubMed).
Animal data is also a dead end for a global brand. The EU bans animal testing of finished cosmetics and their ingredients, and bans marketing products tested that way (European Commission). Human models are the practical route.
So an ingredient checker that shows no red flags is a good screening step, not substantiation. Even a famously light oil needs the finished-product test, a point the squalane sourcing guide makes for one of K-beauty’s favorite emollients.
Which Test Supports Which Claim?
Match the test to the exact words on the pack. A back-patch comedogenicity test supports non-comedogenic, an in-use test on acne-prone skin supports suitable for acne-prone skin, and an irritation test supports neither.
| Claim on the pack | Test design | What the lab measures | Watch-out |
|---|---|---|---|
| “Non-comedogenic” or “won’t clog pores” | Human comedogenicity test: product patched on the upper back under occlusion, repeated over several weeks | Microcomedones counted from follicle samples taken with fast-setting glue, compared with controls | Closest fit for the claim; uses comedone-prone volunteers |
| “Suitable for acne-prone skin” or “tested on acne-prone skin” | In-use test: volunteers with acne-prone skin use the product as directed | Comedones and blemishes graded at the start and the end | Mirrors real use; the panel definition decides what it proves |
| “Dermatologist tested” | Any study run or graded by a dermatologist | Only that a dermatologist supervised | Says nothing about pores on its own |
| “Hypoallergenic” or low irritation | HRIPT or patch test | Irritation and sensitization | No comedone endpoint; see HRIPT vs clinical vs consumer testing |
| “Treats acne” or “helps prevent new blemishes” | Not a cosmetic claim in the US | OTC acne drug rules apply instead | Actives limited to benzoyl peroxide, salicylic acid, sulfur and resorcinol combinations (21 CFR 333 Subpart D) |
A human comedogenicity test is the closest match because it measures the claim itself: new plugs in the follicle. The in-use test answers a different question, how acne-prone skin fares during normal use, so its results support a narrower phrase.
Korea Already Treats Acne-Prone Claims as Test Claims
Korean law makes the seller prove every factual claim. In 2011, Korea’s regulator classed “suitable for acne-prone skin” as a claim allowed only with objective proof, such as human test data (Korea.kr policy briefing). Your Korean ODM will not be surprised by the request.
The Cosmetics Act puts the burden on the brand. Sellers must be able to prove factual claims, and MFDS can ask for the data. A seller that misses the 15-day deadline must stop the ad (Cosmetics Act Article 14, via the Korea Cosmetic Association). The enforcement rule lists what counts: human application test data, in vitro test data, or research and survey data of the same standard, produced with a scientific and objective method.
MFDS’s substantiation notice also spells out what a human test report must contain, including subject selection criteria, the number of subjects with a reason, and the statistics. One example in that notice is blunt: a patent for an acne-improving composition does not prove that a product improves acne.
Acne relief itself sits on a separate track. In Korea, products that help relieve acne-prone skin are functional cosmetics limited to rinse-off cleansers. They must also state that they are not medicines (ChemLinked summary of the functional cosmetics rules). The rulebook keeps moving: in August 2026, MFDS proposed accepting in vitro data for SPF and PA claims (MFDS notice).
“I’m Liz, I run altameet from Manhattan, NYC. The cheapest moment to plan a comedogenicity test is before the formula is locked, because every later change means a retest. If you want a quick gut-check on which claim your Korean ODM’s test can carry in the US, I’ll give you 15 minutes free.”
How Do You Run a Non-Comedogenic Test Through a Korean ODM?
Run it in six steps. Lock the formula, write the claim, get the protocol, check the panel and method, match the test article, and file an English report.
- Lock the formula. Fragrance, emollients, silicones and pigment load all change the result, so test the version you will ship.
- Write the claim first. Choose non-comedogenic, suitable for acne-prone skin, or both, and tell the ODM which design each one needs.
- Ask for the protocol before you pay. Your ODM will book the study through its own research center or an outside human-test lab. The protocol shows what the final report will be able to say.
- Check the panel and method. Look for comedone-prone or acne-prone volunteers, written inclusion and exclusion criteria, the subject count with a reason, the duration, and who grades the skin.
- Match the test article. The report should name your formula code and lot, not a sister formula from the ODM’s catalog.
- Get the report in English and file it. Keep the Korean original too, and store both in your claim file.
That claim file sits next to, not inside, your safety records. MoCRA requires the responsible person to keep records of adequate safety substantiation, and FDA notes that the law does not require specific tests for it (FDA MoCRA overview). If you are mapping the whole launch, the step-by-step guide to starting a K-beauty brand shows where testing fits.
Five Mistakes That Undercut a Non-Comedogenic Claim
Weak claims usually fail for plain reasons: the wrong proof, the wrong product or the wrong words. These five are the easiest to avoid.
- Using an ingredient checker as proof. Screening tools help you choose raw materials. They do not test your formula.
- Testing a prototype, then changing it. A new fragrance or a heavier emollient after the test means the report no longer describes the product.
- Stretching one test across a line. A cream report does not cover the cleanser, the sun stick or the tinted version.
- Inflating the claim. “Clinically proven non-comedogenic” promises more than a report that says tested. The FTC holds you to the level of proof your words imply.
- Sliding into drug language. “Helps prevent new blemishes” and “penetrates pores to clear blackheads” are OTC acne drug statements in the US. Talk about pores, not acne, unless the product is built as an OTC drug, which acne products sold as OTC drugs walks through.
When Should You Book the Test?
Book it right after formula lock and before the label artwork is final. The study takes weeks, and its result decides your claim wording.
The 1982 human model used about a month of occlusion on the upper back (1982 abstract). The 2006 study patched products three times a week for four weeks (2006 abstract). Volunteer recruitment and report writing come on top of that.
Run it alongside stability work on the same formula code, not after it. Reading Korean stability and challenge test reports covers that side of the file. If the result comes back weak, you still have three moves: drop the claim, use a narrower phrase the data supports, or reformulate and retest.
Non-Comedogenic Claim Checklist
The questions to ask your Korean ODM before you book the test, on one page.
Frequently Asked Questions
Is non-comedogenic the same as oil-free?
No. Oil-free describes what is left out of the formula. Non-comedogenic describes how the finished product behaved in a test. Some oils test well and some oil-free formulas do not, which is why the finished-product test matters.
Can a Korean “suitable for acne-prone skin” report support a US non-comedogenic claim?
Sometimes. If the Korean study was an in-use test on acne-prone volunteers, it fits “tested on acne-prone skin” more closely than a pore claim. Read the protocol: the panel, duration, endpoints and formula code all have to match your US wording.
Does MoCRA require a non-comedogenic test?
No. MoCRA requires safety substantiation records, not claim tests. Claim proof is a separate file you build for truthful labeling and FTC substantiation. For registration and listing, see the FDA import and MoCRA guide for Korean skincare.
Can a product pass the test and still break someone out?
Yes. A comedogenicity test shows how a product behaved on a panel, not how every person reacts. Keep the claim factual and route customer reports through your adverse event process.
Do sunscreens and tinted products need anything different?
In the US, a sunscreen is an OTC drug, so a pore claim on a sunscreen sits on a drug label and still needs proof. For tinted products, ask the lab whether one shade can represent the range and keep that rationale in your file.
By Liz Song, K-beauty sourcing consultant.
